Pulmonary hypertension is a rather uncommon, apparently serious, and etiologically diverse sickness that has an inadmissibly high 5-year death rate (≈50%), more regrettable than numerous malignancies. Dysregulated immune cycles underlie pulmonary hypertension pathobiology, regardless of the pathogenic beginning, especially relating to pulmonary vascular renovating. Accordingly, an assortment of proinflammatory pathways has been mooted as novel therapeutic targets. One such pathway includes the group of intrinsic immune controllers known as inflammasomes. Moreover, a new and arising idea is separating between anti-inflammatory approaches versus those that support pro-resolving pathways. This researched study will momentarily present inflammasomes and look at recent writing concerning their job in pulmonary hypertension. In addition, there are two approaches – pro-resolution and inflammation-suppressing. The study will also investigate the contrasts between the two approaches. Furthermore, it will also explore how the two approaches are linked to inflammasomes. At long last, we will also research new roads for focusing on inflammation in pulmonary hypertension by strategies targeted towards anti-inflammation or resolving inflammation.